July 2026—Among its many peculiarities, medicine dwells in interstitial spaces—between seeing a problem and addressing it; between the (in)actions of one specialty and another; between practice and practice guidelines; between overtreatment and targeted treatment; between widespread access and boutique care.
July 2026—When Neha Gupta, MD, attended a fellowship fair early in her second year of residency, she was caught off guard by the number of programs already accepting applications from her peers. It was only March, and she had been told she could apply for her fellowship in late summer.
July 2026—An International Association for the Study of Lung Cancer panel provided recommendations in 2020 on how to process lung cancer resection specimens and define pathologic response after neoadjuvant therapy. They were intended as guidance for clinical trials but offered as a suggestion for good clinical practice.
June 2026—CAP TODAY publisher Bob McGonnagle spoke on March 12 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Jesse M. Young, PhD, medical director for TriCore Research Institute’s research and clinical trials department and director of point-of-care testing. Dr. Young is also clinical assistant professor at the University of New Mexico.
Bob McGonnagle: Dr. Young, tell us about TriCore and the laboratories you oversee.
Dr. Young (TriCore): TriCore Reference Laboratory is a full-service diagnostic laboratory. The core laboratory offers about 2,900 test codes and has a modality similar to that of Labcorp and Quest, but we’re focused on New Mexican populations. We serve most of the hospitals in the area and have statewide collection sites whereby we’re trying to expand health care and provide coverage for our communities so everyone in the state has access to health care near their home instead of having to drive six hours to the nearest collection site, drive home, and then be called back for a critical value. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
CAP TODAY RECOMMENDS
Discover how Epredia Lab 360 transforms modern pathology workflows with a fully integrated solution combining instrumentation, consumables, and services. Learn More
July 2026—There’s an important election coming up, and it’s not the one you’ve been hearing about on the news. Voting will begin soon for new members of the CAP’s Board of Governors, and I urge you to take part.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: chemistry/immunoassay analyzers for mid- and high-volume labs
July 2026—Roche’s new Cobas Mass Spec solution will be on display this month at the ADLM meeting, as will Diasorin’s new Liaison Nes, Siemens Healthineers’ Atellica DT 250, and much more. CAP TODAY publisher Bob McGonnagle spoke online in late May with representatives of Roche, Diasorin, Sebia, and Siemens Healthineers about how their instruments will solve some of laboratories’ pressing problems. The conversation follows.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
September 2025—Roche has received the CE mark for its Elecsys pTau181 test to measure phosphorylated tau 181 protein, an indicator of amyloid pathology. The test, developed in collaboration with Eli Lilly, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer’s disease as the cause of cognitive decline.
The CE mark for the test was based on data from a prospective, multicenter study that included 787 patients in the United States, Europe, and Australia. The study showed the test was able to rule out Alzheimer’s disease with a high negative predictive value of 93.8 percent, based on a 22.5 percent prevalence of amyloid positivity according to PET scans, and with 83.6 percent sensitivity.